Skip to main content
Delfa

← Trials/Trial dossier/NCT06066710

RecruitingPhase EARLY_1

Propranolol in Primary Progressive Aphasia

Trial of Propranolol in Older Adults with Primary Progressive Aphasia

Asset

Propranolol

Listed sites

1

Recruiting sites

1

Enrollment

30

estimated

Study population

Frontotemporal dementia

Key I/E criterion

•Age ≥50

Primary endpoint

•Neuropsychological Assessment Battery Naming Test

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID2097152
NCT IDNCT06066710

Timeline

Milestones

Study first posted2023-10-04actual
Study start2025-01-13actual
Last update posted2025-03-28actual
Primary completion2026-12estimated (month precision)
Study completion2027-12estimated (month precision)

Assets

Drug assets

Propranolol

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•1. Age: 50 and older
•2. Primary Progressive Aphasia diagnosis
•3. Native English speaker

Exclusion criteria

•1. Unable to provide consent
•2. Taking alpha 2 agonists (clonidine and guanfacine)
•3. Other major psychological or neurological diagnosis
•4. Major head trauma that contributed to their condition
•5. Allergic reaction to adhesives
•6. Uncorrected vision/hearing impairments
•7. Diabetes
•8. Reactive airway disease
•9. Untreated hypothyroidism
•10. Bradyarrhythmia
•11. Unexplained syncope
•12. Pregnancy (assessed verbally on the days of MR imaging)
•13. Drugs that interact with propranolol, such as alpha 2 agonists
•14. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Executive function / language
2
Behavior / neuropsychiatric
1

Executive function / language

2 endpoints
Primary/protocol endpoint

Change in Neuropsychological Assessment Battery Naming Test

Time frame:Day 1, 4 Weeks, 8 Weeks, 10 Weeks, 14 Weeks,18 Weeks

change from baseline, improvement

Secondary/protocol endpoint

Change in Semantic Word Fluency Tasks

Time frame:Day 1, 8 Weeks,18 Weeks

change from baseline, improvement

Behavior / neuropsychiatric

1 endpoint
Secondary/protocol endpoint

Change in State-Trait Anxiety Inventory for Adults

Time frame:Day 1, 4 Weeks, 8 Weeks, 10 Weeks,14 Weeks,18 Weeks

change from baseline, improvement

Publications (13)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.